![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
The Pharmacokinetics of Ledipasvir, an HCV-Specific NS5A Inhibitor, in HCV-Uninfected Subjects With Severe Renal Impairment
|
|
|
Reported by Jules Levin
AASLD 2014 Nov 7-11 Boston
Erik Mogalian,1 Anita Mathias,1 Jenny Yang,1 Lisa Moorehead,1 Maria Hernandez,1 Kenneth Lasseter,2 Daniel K. Ries,3 Richard A. Robson,4 Gemot K. Klein5
1Gilead Sciences, Inc., Foster City, CA; 2Clinical Pharmacology of Miami, Inc., Miami, FL; 3Prism Clinical Research, St Paul, MN; 4Christchurch Clinical Studies Trust, Ltd, Christchurch, New Zealand; 5APEX GmbH, Bremen, Germany
![AASLD1.gif](../images/121514/121514-4/AASLD1.gif)
![AASLD2.gif](../images/121514/121514-4/AASLD2.gif)
![AASLD3.gif](../images/121514/121514-4/AASLD3.gif)
![AASLD4.gif](../images/121514/121514-4/AASLD4.gif)
![AASLD5.gif](../images/121514/121514-4/AASLD5.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|